Streetbeat News

Stock Prices

ALZN

Alzamend Neuro has confirmed positive topline results from June 2023, identifying a maximum tolerated dose as assessed by an independent safety review committee.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has announced the full data set for its Phase IIA clinical trial of AL001, a treatment for dementia related to Alzheimer's. This development is a significant step in the company's research efforts.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

SYF

Synchrony Financial shares rose after the company reported better-than-expected Q3 results and increased its FY24 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:29 am

INTC

JBHT

NVCR

QQQ

SPY

US stock futures indicate a mixed opening after a tech sell-off led by ASML's weak forecast. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) show slight premarket gains. J.B. Hunt Transport Services (JBHT) and NovoCure (NVCR) see significant premarket rises due to positive earnings and FDA approval, respectively. Intel (INTC) declines on Qualcomm's investment delay. Oil prices continue to pressure energy stocks.

Portfolio Pulse from Shanthi Rexaline

October 16, 2024 | 11:29 am

NVCR

The FDA has approved NovoCure's Optune Lua, a portable device that uses tumor-treating electric fields, for use with certain inhibitors or docetaxel in treating metastatic non-small cell lung cancer. The approval follows positive results from the Phase 3 LUNAR study, showing significant improvements in overall survival rates. NovoCure's stock (NVCR) rose by 26.20% following the news.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:28 am

OMC

Omnicom Group's shares are trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:28 am

GM

TSLA

Tesla dominated the US EV market in Q3 2024, with the Model Y, Model 3, and Cybertruck being the top three best-selling models. Tesla's overall sales increased by 6.6% compared to the previous year. General Motors was the second best-selling EV maker, with a significant increase in GMC's Hummer EV sales.

Portfolio Pulse from Anan Ashraf

October 16, 2024 | 11:21 am

CSTL

Castle Biosciences has published two studies supporting the clinical need for its MyPath Melanoma gene expression profile test, which aids in diagnosing ambiguous melanocytic lesions.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:12 am

APLS

Apellis Pharmaceuticals announced an oral presentation on the Phase 3 VALIANT study of Pegcetacoplan in C3G and primary IC-MPGN at the American Society of Nephrology Kidney Week.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:11 am

EYEN

Eyenovia will present successful Phase 3 study results of Clobetasol Propionate Suspension 0.05% (APP13007) for treating inflammation and pain post-ocular surgery at the American Academy of Ophthalmology 2024 Expo.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:09 am